Where is menstruation in global health policy? The need for a collective understanding.

From both an academic and a policy angle, menstruation is receiving an unprecedented level of attention. Within the academic literature, there are many different normative arguments being furthered for how menstruation be understood and framed - variously, that it should be understood as an issue of rights, justice, health or hygiene management. Yet less attention has been paid to the step preceding these normative arguments - how menstruation actually understood at present within global health policy.

Successful Treatment of Primary Acanthamoeba Cutis in a Patient With Chronic Lymphocytic Leukemia on Acalabrutinib.

Primary cutaneous amoebiasis is rare, and typically affects immunocompromised patients and presents with unique clinical and histopathologic changes. Untreated, the infection could progress to involve the central nervous system, which is almost universally fatal. We present a case of primary cutaneous acanthamoebiasis in a patient with chronic lymphocytic leukemia on acalabrutinib.

Neuroinflammatory pathways and potential therapeutic targets in neonatal post-hemorrhagic hydrocephalus.

Background: Post-hemorrhagic hydrocephalus (PHH) is a severe complication in premature infants following intraventricular hemorrhage (IVH). It is characterized by abnormal cerebrospinal fluid (CSF) accumulation, disrupted CSF dynamics, and elevated intracranial pressure (ICP), leading to significant neurological impairments.

Objective: This review provides an overview of recent molecular insights into the pathophysiology of PHH and evaluates emerging therapeutic approaches aimed at addressing its underlying mechanisms.

Maternal Perception of Infant Sleep and Bonding in Opioid Use Disorder.

Objective: Infant sleep problems are common in early infancy and can negatively influence maternal-infant bonding. As opioid-exposed neonates are at increased risk of sleep difficulties, we examined the association between maternal perception of infant sleep difficulties and maternal-infant bonding among dyads affected by maternal opioid use disorder (OUD), from birth through 6 months.

Methods: We enrolled 100 birthing people (participants) between 6 months and 2 years postpartum who had received medications for OUD during their pregnancy.